J. Horton, M.D., F.A.C.P.; K. B. Olson, M.D., F.A.C.P.; B. Shnider, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Fluorouracil is a palliative antitumor agent whose use is limited by toxicity. Several methods for reducing toxicity have been described, but the package insert still recommends a course of daily injections to hospital-confined patients. Such a course, in our hands, has resulted in severe morbidity and 12 to 15% mortality.
This study compared three dose levels, 7.5, 15, and 20 mg/kg body weight, given intravenously, undiluted, at weekly intervals without a loading course to patients with advanced cancer. Treatment was continued for 8 weeks and longer if remission, defined as greater than 50% shrinkage of tumor, occurred. Two hundred thirty-nine
Horton J, Olson KB, Shnider B. Safer Fluorouracil—A Weekly Schedule.. Ann Intern Med. ;72:799. doi: 10.7326/0003-4819-72-5-799_1
Download citation file:
Published: Ann Intern Med. 1970;72(5):799.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use